A Ubl/ubiquitin switch in the activation of Parkin

Abstract

Mutations in Parkin and PINK 1 cause an inherited early‐onset form of Parkinson's disease. The two proteins function together in a mitochondrial quality control pathway whereby PINK 1 accumulates on damaged mitochondria and activates Parkin to induce mitophagy. How PINK 1 kinase activity releases the auto‐inhibited ubiquitin ligase activity of Parkin remains unclear. Here, we identify a binding switch between phospho‐ubiquitin ( pU b) and the ubiquitin‐like domain (Ubl) of Parkin as a key element. By mutagenesis and SAXS , we show that pU b binds to RING 1 of Parkin at a site formed by His302 and Arg305. pU b binding promotes disengagement of the Ubl from RING 1 and subsequent Parkin phosphorylation. A crystal structure of Parkin Δ86–130 at 2.54 Å resolution allowed the design of mutations that specifically release the Ubl domain from RING 1. These mutations mimic pU b binding and promote Parkin phosphorylation. Measurements of the E2 ubiquitin‐conjugating enzyme UbcH7 binding to Parkin and Parkin E3 ligase activity suggest that Parkin phosphorylation regulates E3 ligase activity downstream of pU b binding. image A conformational switch between phospho‐ubiquitin binding and release of its ubiquitin‐like (Ubl) domain is a key step in the cascade of PINK 1‐dependent phosphorylation events that lead to activation of Parkin, a ubiquitin ligase implicated in mitochondrial quality control and Parkinson disease. Phosphorylation of ubiquitin on Ser65 induces its binding to Parkin at His302. Phospho‐ubiquitin binding induces a conformational change in Parkin, which releases the Ubl domain from the RING 1 domain. Release of the Ubl domain promotes its phosphorylation on Ser65, which in turn increases Parkin affinity for E2 enzymes and Parkin ubiquitin ligase activity via Cys431.